Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
about
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCIs there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma.MicroRNA-targeted therapeutics for lung cancer treatment.Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC.
P2860
Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is there a progression-free su ...... ive study of Chinese patients.
@en
Is there a progression-free su ...... ive study of Chinese patients.
@nl
type
label
Is there a progression-free su ...... ive study of Chinese patients.
@en
Is there a progression-free su ...... ive study of Chinese patients.
@nl
prefLabel
Is there a progression-free su ...... ive study of Chinese patients.
@en
Is there a progression-free su ...... ive study of Chinese patients.
@nl
P2093
P2860
P921
P356
P1433
P1476
Is there a progression-free su ...... ive study of Chinese patients.
@en
P2093
Jialin Qian
Liwen Xiong
Liyan Jiang
Shaohua Cui
Yanjie Niu
Yizhuo Zhao
P2860
P304
P356
10.1002/CAM4.659
P407
P577
2016-02-16T00:00:00Z